We found a match
Your institution may have rights to this item. Sign in to continue.
- Title
Cáncer de mama Her2-positivo: Terapias sistémicas actuales y experiencia local.
- Authors
Walbaum G., Benjamín; Acevedo C., Francisco; Carrillo B., Diego; Camus A., Mauricio; Manzor V., Manuel; Martínez R., Raúl; Veglia Q., Paulina; Murature S., Geraldine; Salvado U., Valentina; Muñiz M., Sabrina; Merino L., Tomas; Sánchez R., César
- Abstract
Breast cancer (BC) is the leading cause of cancer death for women both worldwide and in Chile. Based on clinical, histological, and molecular features, studies have identified four BC subtypes that correlate with treatment sensitivity. Human Epidermal growth factor Receptor type 2-positive (HER2+) BC re)presents 15%-25% of newly diagnosed breast neoplasms; HER2+ BC is characterized by its aggressive behavior, early recurrence, and higher risk of brain metastasis. In recent years, HER2-targeted therapies have become the mainstay of treatment and have redefined the natural history of this subtype, reducing relapse rates for early-stage patients and increasing survival in advanced-stage patients. Herein we review novel treatment strategies and their mechanisms of action, along with clinical and real-world data. We also provide a summary of currently available treatments for this subtype and our local experience regarding the management of this disease.
- Publication
Revista de Cirugia, 2023, Vol 75, Issue 1, p43
- ISSN
2452-4557
- Publication type
Article
- DOI
10.35687/s2452-454920230011653